OncoZenge
A Swedish biotech company developing opioid-sparing treatments for oral pain.
OncoZenge's lead product is BupiZenge, an oral lozenge formulation of the anaesthetic bupivacaine. The dru's lead indication is oral mucositis, which affects patients receiving cancer treatment. BupiZenge has demonstrated significantly better pain relief compared to standard of care in this indication in a Phase II trial.
Latest OncoZenge News & Features
28 November 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze